Menu
Menu
Di Lorenzo G., Guerra G., Buonerba C.
Major breakthroughs in the evolvin scenario of systemic treatment of prostate cancer.
Minerva Urol Nephrol. 2022 Feb;74(1):130-131. doi: 10.23736/S2724-6051.22.04788-7. PMID: 35272456.
Lorenzo GD, Scafuri L, Costabile F, Pepe L, Scognamiglio A, Crocetto F, Guerra G, Buonerba C.
Fisetin as an adjuvant treatment in prostate cancer patients receiving androgen-deprivation therapy.
Future Sci OA. 2022 Feb 11;8(3):FSO784. doi: 10.2144/fsoa-2022-0002. PMID: 35251698; PMCID: PMC8890115.
Crocetto F, Buonerba L, Scafuri L, Caputo V, Barone B, Sciarra A, Verde A, Calogero A, Buonerba C, Lorenzo GD.
COVID-19 and prostate cancer: a complex scenario with multiple facets.
Future Sci OA. 2021 Oct;8(1):FSO. doi: 10.2144/fsoa-2021-0113. Epub 2021 Nov 23. PMID: 34898669; PMCID: PMC8621215.
Crocetto F, di Zazzo E, Buonerba C, Aveta A, Pandolfo SD, Barone B, Trama F, Caputo VF, Scafuri L, Ferro M, Cosimato V, Fusco F, Imbimbo C, Di Lorenzo G.
Kaempferol, Myricetin and Fisetin in Prostate and Bladder Cancer: A Systematic Review of the Literature. Nutrients.
2021 Oct 23;13(11):3750. doi: 10.3390/nu13113750. PMID: 34836005; PMCID: PMC8621729.
Scafuri L, Sciarra A, Crocetto F, Ferro M, Buonerba C, Ugliano F, Guerra G, Sanseverino R, Lorenzo GD.
Does perioperative systemic therapy represent the optimal therapeutic paradigm in organ-confined, muscle-invasive urothelial carcinoma?
Future Sci OA. 2021 Oct 28;7(9):FSO770. doi: 10.2144/fsoa-2021-0092.
PMID: 34737893; PMCID: PMC8558855.
Buonerba C, Grivas P, Di Lorenzo G.
Perioperative Immune Checkpoint Inhibitors in Renal Cell and Urothelial Carcinomas: An Exciting New Paradigm under Investigation?
Oncology. 2021;99(11):681-685. doi: 10.1159/000518741. Epub
2021 Sep 8. PMID: 34515202.
Sciarra A, Buonerba C, Lorenzo GD, Scafuri L.
Contralateral prophylactic mastectomy in male breast cancer: where do we stand?
Future Sci OA. 2021 Jul 2;7(8):FSO746. doi: 10.2144/fsoa-2021-0071. PMID: 34295542; PMCID: PMC8288221.
Crocetto F, Ferro M, Buonerba C, Bardi L, Dolce P, Scafuri L, Mirto BF, Verde A, Sciarra A, Barone B, Calogero A, Sagnelli C, Busetto GM, Del Giudice F, Cilio S, Sonpavde G, Di Trolio R, Della Ratta GL, Barbato G, Di Lorenzo G.
Comparing cardiovascular adverse events in cancer patients: A meta-analysis of combination therapy with angiogenesis inhibitors and immune checkpoint inhibitors versus angiogenesis inhibitors alone.
Crit Rev Oncol Hematol. 2023 Jun 21;188:104059. doi: 10.1016/j.critrevonc.2023.104059.
Ferro M, Crocetto F, Tataru S, Barone B, Dolce P, Lucarelli G, Sonpavde G, Musi G, Antonelli A, Veccia A, Terracciano D, Busetto GM, Giudice FD, Marchioni M, Schips L, Porpiglia F, Fiori C, Carrieri G, Lasorsa F, Verde A, Scafuri L, Buonerba C, Di Lorenzo G.
Predictors of Efficacy of Immune Checkpoint Inhibitors in Patients With Advanced Urothelial Carcinoma: A Systematic Review and Meta-Analysis
Clin Genitourin Cancer. 2023 May 27:S1558-7673(23)00137-4.
Di Lorenzo G, Ingenito C, Iervolino M, Sosto G, Sergianni P, Primiano F, Piscosquito A, Iuliucci MR, Rubino R, Gatani S, Ugliano F, Scafuri L, Costabile F, D’Ambrosio B, D’Antonio A, Crescenzo A, Cappuccio F, Buonerba C.
PREVES: A Population-Based Survey Focused on Cancer and Nutrition.
Oncology. 2023;101(6):369-374. doi: 10.1159/000530626. Epub 2023 Apr 13. PMID: 37054688